Andrea Alimonti

Andrea Alimonti has been a leading figure in understanding therapy-induced senescence (TIS) in cancer, demonstrating that conventional chemotherapy and targeted agents can trigger senescence in tumor cells that paradoxically promotes long-term treatment failure through SASP. His research in prostate cancer revealed that PTEN loss triggers a senescence response that is initially tumor-suppressive but eventually promotes immune evasion and tumor progression. He pioneered the one-two punch concept of first inducing senescence with therapy then eliminating senescent cancer cells with senolytics. His work has defined the molecular basis for combining pro-senescence therapy with senolytic clearance in clinical oncology.